Entering text into the input field will update the search result below

Amgen Lumakras/Vectibix combo shows promise in phase 1 trial in colorectal cancer

Sep. 12, 2022 5:53 AM ETAmgen Inc. (AMGN) StockBy: Ravikash Bakolia, SA News Editor
  • Amgen (NASDAQ:AMGN) said Lumakras in combination with its other drug Vectibix showed encouraging efficacy and safety in certain patients with colorectal cancer in a phase 1b study called CodeBreaK 101.
  • In total, 40 patients with heavily pre-treated (median of two prior lines of

Recommended For You

More Trending News

About AMGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AMGN--
Amgen Inc.